Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Vladan Vucinic, David Fandrei, Janine Kirchberg, Enrica Bach, Mandy Brueckner, Kathleen Friedrich, Carmen Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Simone Heyn, Uwe Platzbecker, Maximilian Merz

Blood (2024) 144 (Supplement 1): 2094.

https://doi.org/10.1182/blood-2024-207117

Published: 2024

Journal Articles

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 453.

https://doi.org/10.1182/blood-2023-187371

Published: 2023

Journal Articles

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Vladan Vucinic, Janine Kirchberg, Mandy Brueckner, Patrick Born, Luise Fischer, Enrica Bach, Nora Grieb, Simone Heyn, Christina Kloetzer, Klaus H Metzeler, Sandra Hoffmann, Carmen Herling, Marco Herling, Georg-Nikolaus Franke, Sebastian Schwind, Song-Yau Wang, Madlen Jentzsch, Uwe Platzbecker, Maximilian Merz

Blood (2023) 142 (Supplement 1): 3521.

https://doi.org/10.1182/blood-2023-182222

Published: 2023

Journal Articles

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2023-188367

Published: 2023

Journal Articles

Increased Bone Turnover and Decreased BCMA Levels in Patients with Response to Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Jule Ussmann, Luise Fischer, Patrick Born, Nora Grieb, Sandra Hoffmann, Ronny Baber, Song-Yau Wang, Christina Kloetzer, Simone Heyn, Marco Herling, Carmen Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Lorenz Hofbauer, Uwe Platzbecker, Vladan Vucinic, Heike Weidner, Maximilian Merz

Blood (2023) 142 (Supplement 1): 6643.

https://doi.org/10.1182/blood-2023-185643

Published: 2023

Journal Articles

Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed Therapies

Maximilian Merz, Vladan Vucinic, Song Yau Wang, Christina Kloetzer, Birthe Schetschorke, Jan Sonntag, Jule Ussmann, Saskia Hell, Simone Heyn, Sandra Hoffmann, Enrica Bach, Klaus H. Metzeler, Sebastian Schwind, Marco Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 12492–12493.

https://doi.org/10.1182/blood-2022-164591

Published: 2022

Journal Articles

Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Blood (2022) 140 (Supplement 1): 4207–4208.

https://doi.org/10.1182/blood-2022-166241

Published: 2022

Journal Articles

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Blood (2016) 128 (22): 1066.

https://doi.org/10.1182/blood.V128.22.1066.1066

Published: 2016

Journal Articles

Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma

Madlen Jentzsch, MD, Elena Ruschpler, Sabine Leiblein, PhD, Yvonne Remane, Jan-Phillip Stümpel, MD, Georg-Nikolaus Franke, MD, Simone Heyn, MD, Nadja Jaekel, MD, Susann Schulze, MD, Song-Yau Wang, MD, Wolfram Poenisch, MD, Claudia Nehring, MD, Sebastian Schwind, MD, Dietger Niederwieser, MD, Vladan Vucinic, MD

Blood (2015) 126 (23): 5439.

https://doi.org/10.1182/blood.V126.23.5439.5439

Published: 2015

Journal Articles

Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO)

Blood (2014) 124 (21): 280.

https://doi.org/10.1182/blood.V124.21.280.280

Published: 2014

Journal Articles

Reduced Intensity Conditioning Allogeneic Haematopoietic Stem Cell Transplantation - a Treatment Option in Elderly or Comorbid Patients with Acute Lymphatic Leukemia

Vladan Vucinic, MD, Theresa Tumewu, Georg-Nikolaus Franke, MD, Sebastian Schwind, MD, Nadja Jaekel, MD, Simone Heyn, MD, Wolfram Poenisch, MD, Haifa Kathrin Al-Ali, MD, Sabine Leiblein, Rainer Krahl, PhD, Madlen Jentzsch, MD, Gerhard Behre, MD, Dietger Niederwieser, MD

Blood (2014) 124 (21): 5945.

https://doi.org/10.1182/blood.V124.21.5945.5945

Published: 2014

Journal Articles

Successful Stem Cell Mobilization and Autologous Stem Cell Transplantation after Pretreatment Consisting of Bendamustine, Prednisone and Bortezomib (BPV) in 35 Patients with Newly Diagnosed/Untreated Multiple Myeloma

Blood (2014) 124 (21): 5900.

https://doi.org/10.1182/blood.V124.21.5900.5900

Published: 2014

Journal Articles

Increasing The Dose Of AraC In Consolidation Therapy Does Not Lead To Higher Overall Survival Or Improved Relapse Incidence In Patients With AML Over The Age Of 60 Years

Blood (2013) 122 (21): 2645.

https://doi.org/10.1182/blood.V122.21.2645.2645

Published: 2013

Journal Articles

Combined Bendamustine, Prednisone and Bortezomib (BPV) in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2012) 120 (21): 1855.

https://doi.org/10.1182/blood.V120.21.1855.1855

Published: 2012

Journal Articles

Combined Bendamustine, Prednisolone and Lenalidomide (RBP) In Refractory or Relapsed Multiple Myeloma. First Results of a Phase I Clinical Trial

Wolfram Pönisch, Simone Heyn, Ina Wagner, Martin Mohren, MD, Franz-Albert Hoffmann, Frank Schüler, Marion Schmalfeld, Haifa K. Al-Ali, Nadja Jäkel, Dietger W Niederwieser, MD

Blood (2010) 116 (21): 1971.

https://doi.org/10.1182/blood.V116.21.1971.1971

Published: 2010

Journal Articles

Outcome of Relapsed Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) after Allogeneic Hematopoietic Cell Transplantation (HCT).

Simone Heyn, MD, Rainer Krahl, PhD, Thoralf Lange, MD, Ann-Kathrin Eisfeld, MD, Dietger Niederwieser, MD, Haifa K. Al-Ali, MD

Blood (2007) 110 (11): 3230.

https://doi.org/10.1182/blood.V110.11.3230.3230

Published: 2007

Journal Articles

Bortezomib in Combination with Bendamustine and Prednisone in the Treatment of Patients with Refractory/Relapsed Multiple Myeloma.

Wolfram Poenisch, MD, Malvina Bourgeois, Song-Yau Wang, Simone Heyn, Nadja Jaekel, Leanthe Braunert, Robert Rohrberg, MD, Hans Juergen Hurtz, MD, Franz Albert Hoffmann, MD, Andreas Schwarzer, MD, Cornelia Becker, MD, Haifa Al Ali, MD, Dietger W. Niederwieser, MD

Blood (2007) 110 (11): 2723.

https://doi.org/10.1182/blood.V110.11.2723.2723

Published: 2007

Journal Articles

Increased Leukaemia Free Survival (LFS) in Patients with Cytogenetic High Risk AML after Related or Unrelated Hematopoietic Cell Transplantation (HCT) Compared to Chemotherapy in the OSHO 96 and 2002 Studies.

Blood (2006) 108 (11): 264.

https://doi.org/10.1182/blood.V108.11.264.264

Published: 2006

Journal Articles

Early Allogenic Transplantation Improves Overall Survival (OS) and Event Free Survival (EFS) Independently of the Applied Chemotherapy in AML Patients with Unfavourable Cytogenetic Karyotype.

Blood (2006) 108 (11): 1921.

https://doi.org/10.1182/blood.V108.11.1921.1921

Published: 2006

NARROW

Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Increased Bone Turnover and Decreased BCMA Levels in Patients with Response to Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed Therapies

Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma

Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO)

Reduced Intensity Conditioning Allogeneic Haematopoietic Stem Cell Transplantation - a Treatment Option in Elderly or Comorbid Patients with Acute Lymphatic Leukemia

Successful Stem Cell Mobilization and Autologous Stem Cell Transplantation after Pretreatment Consisting of Bendamustine, Prednisone and Bortezomib (BPV) in 35 Patients with Newly Diagnosed/Untreated Multiple Myeloma

Increasing The Dose Of AraC In Consolidation Therapy Does Not Lead To Higher Overall Survival Or Improved Relapse Incidence In Patients With AML Over The Age Of 60 Years

Combined Bendamustine, Prednisone and Bortezomib (BPV) in Patients with Relapsed or Refractory Multiple Myeloma

Combined Bendamustine, Prednisolone and Lenalidomide (RBP) In Refractory or Relapsed Multiple Myeloma. First Results of a Phase I Clinical Trial

Outcome of Relapsed Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) after Allogeneic Hematopoietic Cell Transplantation (HCT).

Bortezomib in Combination with Bendamustine and Prednisone in the Treatment of Patients with Refractory/Relapsed Multiple Myeloma.

Increased Leukaemia Free Survival (LFS) in Patients with Cytogenetic High Risk AML after Related or Unrelated Hematopoietic Cell Transplantation (HCT) Compared to Chemotherapy in the OSHO 96 and 2002 Studies.

Early Allogenic Transplantation Improves Overall Survival (OS) and Event Free Survival (EFS) Independently of the Applied Chemotherapy in AML Patients with Unfavourable Cytogenetic Karyotype.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only